Precision therapeutics can individualize depression treatment: Ann Moyer, M.D., Ph.D., and Paul Jannetto, Ph.D.
Ann Moyer, M.D., Ph.D., and Paul Jannetto, Ph.D., explain how precision therapeutics can improve treatment for patients with major depressive disorder. The optimal antidepressant medication and dose vary among individuals. Pharmacogenomic testing and ther
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
(00:31)
Can you both tell us a little bit about yourselves and your backgrounds? Dr. Moyer, do you want to start?
(01:51)
Your background, Dr. Janetto?
(02:47)
Please provide an overview of major depressive disorder and the test that Mayo Clinic Laboratories has available for therapeutic drug monitoring as well as pharmacogenomics.
(07:05)
Which patients should have this testing, and when should it be performed?
(11:33)
What alternative test options are available, and how do they compare?
(15:37)
How are the results used in patient care?